// App-Quantinova.ai

PB0073 : Matrix metalloproteinases are associated with poor prognosis in hospitalized patients with COVID-19

Researchers

Presenter

  • M. Marcos-Jubilar

Principal Investigators

  • J. Orbe

  • M. Lozano

  • R. Lecumberri

Medical Centers

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Navarra, Spain

  • Clínica Universidad de Navarra-Pamplona, Navarra, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Infectious Diseases (ID)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Coronavirus disease

Biomarkers

  • Matrix metalloproteinase

  • TIMP Metallopeptidase Inhibitor 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved